Lung cancer trial aims to unlock immune secrets during chemo and immunotherapy
NCT ID NCT04432142
First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This study looks at how the immune system changes in people with stage III non-small cell lung cancer during chemoradiation followed by the immunotherapy drug durvalumab. Researchers want to find patterns in immune cells that could predict how well a patient responds to treatment. About 45 adults will participate, and the goal is to gather information to improve future therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Maastricht Radiation Oncology (MAASTRO clinic)
Maastricht, 6229 ET, Netherlands
Conditions
Explore the condition pages connected to this study.